Analysis of the Weaknesses of the Florida Senate Bill 1159, Solution to Oral Parity
Authors
Nicole Wenzel
Florida Atlantic University
Keywords:
Florida Senate Bill 1159, Florida Public Health Administration, Health care law, Cancer, Florida, Clinical trials cost, Medicare, Cancer drug costs, Health care insurance
Abstract
The cost of orally administered anticancer medications has risen significantly, and patients cannot afford to sustain these prices without sacrificing their financial security. As a result, Florida Senate Bill 1159 was enacted. This bill requires private insurance companies to provide coverage of orally administered cancer medications on a favorable basis. Does this bill solve the problem? The bill’s exclusion of uninsured cancer patients and Medicare recipients diminishes the benefits of the bill as these people are numerous in Florida. In order to rectify this weakness, a price ceiling on the clinical trial costs of drug manufacturers would provide an effective solution that benefits all cancer patients
Author Biography
Nicole Wenzel, Florida Atlantic University
Nicole Wenzel is a senior Accounting major at FAU with Business Law and Economics minors. She plans to begin the Certified Public Accountant examinations this year. Her plans include completing her degree in Fall 2014 and furthering her education in Taxation Law by attending law school.
